Barinthus Biotherapeutics files Form 3 for officer

Barinthus Biotherapeutics plc filed an initial insider ownership report for Douglas J. Swirsky, who serves as Principal Accounting Officer.

Rhea-AI Filing Summary

Barinthus Biotherapeutics plc filed an initial insider ownership report for Douglas J. Swirsky, who serves as Principal Accounting Officer. This Form 3 filing establishes his status as an executive officer and discloses that there were no reportable share transactions or derivative positions included in this submission.

Key Terms

Principal Accounting Officer, ten_percent_owner, transactionSummary

3 terms

Principal Accounting Officer financial

"officer_title": "Principal Accounting Officer""

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

ten_percent_owner regulatory

""is_ten_percent_owner": 0"

transactionSummary regulatory

""transactionSummary": {"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Barinthus Biotherapeutics (BRNS) Form 3 filing report for Douglas J. Swirsky?

The Form 3 filing reports that Douglas J. Swirsky is a Principal Accounting Officer of Barinthus Biotherapeutics. It serves as his initial insider ownership statement and shows no reported share transactions or derivative positions in this submission.

Does the BRNS Form 3 show any stock purchases or sales by Douglas J. Swirsky?

No, the Form 3 for Douglas J. Swirsky reports no buy, sell, acquire, or dispose transactions. The transaction summary shows zero counts across all categories, indicating only an initial ownership status filing without trading activity.

What insider role does Douglas J. Swirsky hold at Barinthus Biotherapeutics (BRNS)?

Douglas J. Swirsky is identified as an officer of Barinthus Biotherapeutics, serving as Principal Accounting Officer. The Form 3 confirms his executive status for SEC reporting purposes and indicates he is not a director or ten percent owner.

Are there any derivative securities reported in the BRNS Form 3 for Douglas J. Swirsky?

No derivative securities are reported for Douglas J. Swirsky in this Form 3. The derivative summary section is empty, and the transaction summary shows zero derivative transactions and zero exercise activity for options or similar instruments.

Does the Barinthus Biotherapeutics (BRNS) Form 3 indicate any gifts or tax withholding transactions?

The Form 3 indicates no gifts, tax-withholding dispositions, or restructuring-related transfers. Gift count, tax withholding count, and restructuring count are all listed as zero, reflecting that this filing only establishes insider status without reporting movements in securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Swirsky Douglas J

(Last) (First) (Middle)

20400 CENTURY BLVD

SUITE 210

(Street)

GERMANTOWN MARYLAND 20874

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2026

3. Issuer Name and Ticker or Trading Symbol
Barinthus Biotherapeutics plc. [ BRNS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ William Enright, Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)